Abbott Laboratories vs. Pfizer Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| ABT | PFE | |
|---|---|---|
| Market Cap | $198.01 billion | $160.96 billion |
| Revenue (TTM) | $46.59 billion | $63.70 billion |
| Net Income (TTM) | $5.42 billion | $4.37 billion |
ABT leads on 2 of 3 size & scale factors.
Valuation
| ABT | PFE | |
|---|---|---|
| P/E Ratio | 37.66 | 36.76 |
| Price / Book | 3.83 | 1.88 |
| Price / Sales | 4.25 | 2.53 |
PFE leads on 3 of 3 valuation factors.
Profitability
| ABT | PFE | |
|---|---|---|
| Net Margin | 11.65% | 6.86% |
| Return on Equity | 10.48% | 5.11% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | PFE | |
|---|---|---|
| Dividend Yield | 2.17% | 6.16% |
| Payout Ratio | 81.55 | 226.32 |
ABT and PFE split the dividend factors evenly.
Risk & Sentiment
| ABT | PFE | |
|---|---|---|
| Short Interest | 0.57% | 0.88% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, PFE overview, PFE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.